Compare InMode Ltd (INMD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Organon & Co. Common Stock — how do they compare? InMode Ltd trades at $14.29 (market cap $823.46M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 4.4× InMode Ltd's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Organon & Co. Common Stock for 0 Days on average.
| INMD | OGN | |
|---|---|---|
Market Cap | $823.46M | $3.62B |
Volume | 427,627 | 2,892,999 |
Sector | Health | Health |
52-Week High | $16.62 | $13.81 |
52-Week Low | $12.76 | $5.70 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $326.79M | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.305, showing minimal daily movement with a 0.03% gain. The stock maintains a bullish technical signal despite mixed indicators, with RSI suggesting mild overbought conditions. Fundamentally, the company demonstrates strong profitability with 76.52% gross margins and 20.69% net income margins, though 2026 guidance shows potential margin compression. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
The investment outlook balances attractive valuation metrics (P/E of 11.83, EV/EBITDA of 4.68) against cyclical industry headwinds and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings, while technicals suggest near-term consolidation around current levels. Key risks include US platform sales decline and execution on international growth strategy.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
